BITI on NASDAQ
Biotie Therapies
Logo: http://www.biotie.com/~/media/Images/B/Biotie-IR/logo/logo-biotie.png, Non-free logo, via Wikipedia3
Finnish pharmaceutical company
Biotie Therapies Oyj was a Finnish biotechnology and pharmaceutics company that was acquired by Acorda Therapeutics in January 2016. The company's research and development was focused on drugs for neurodegenerative and psychiatric disorders like Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence and post traumatic stress disorder, and inflammatory and fibrotic liver disease. The company's headquarters is in Turku, Western Finland, and it is listed on NASDAQ OMX Helsinki.2 Its shares trade on NASDAQ under the symbol BITI.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 21, 2026.
Overview
- TickerBITI on NASDAQ1
- Industrybiotechnology1
- HeadquartersTurku1
- Websitewww.biotie.com
See how the biggest companies compare on our leaderboards
Biotie Therapies Oyj was a Finnish biotechnology and pharmaceutics company that was acquired by Acorda Therapeutics in January 2016. The company's research and development was focused on drugs for neurodegenerative and psychiatric disorders like Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence and post traumatic stress disorder, and inflammatory and fibrotic liver disease. The company's headquarters is in Turku, Western Finland, and it is listed on NASDAQ OMX Helsinki.2
Corporate structure
Biotie Therapies is part of a group headed by Acorda Therapeutics. 6 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
- Acorda Therapeutics Ardsley, New York, United States
- Biotie Therapies Turku
- Biotie Therapies (Switzerland) Subsidiary · Switzerland
- Acorda Therapeutics Ireland Limited Subsidiary · Ireland
- Civitas Therapeutics, Inc. Subsidiary · Delaware, United States
- Neuronex, Inc. Subsidiary · Delaware, United States
- Biotie Therapies Turku
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.
Products and brands
Selincro (nalmefene)
The company's most advanced product, Nalmefene, for the treatment of alcoholism. Biotie's partner H. Lundbeck A/S received European marketing authorization from the European Commission on 28 February 2013. Lundbeck expects to launch Selincro in its first markets in the middle of 2013.
Studies have shown, that nalmefene has the ability to significantly limit both the patient's average alcohol intake and the number of days with an intake above five units of alcohol. The drug works by removing the patient's desire to drink more, thereby controlling and limiting the intake of alcohol. The drug will be used in tablet form, and taken only according to need. According to the company, this is a novel approach for alcohol dependency treatment; existing treatments are aimed at keeping the patient from drinking and the drugs have to be taken continuously over a longer period of time.
Tozadenant
SYN115, also called tozadenant, was developed as a potential treatment for Parkinson's disease or other CNS disorders. It was an orally administered, potent and [selective inhibitor of the adenosine A2A receptor.
In January 2016, the company was acquired by Acorda Therapeutics, for US$363 million. In November 2017, the company announced discontinuation of the agent following the death of 5 patients enrolled in the tozadenant Phase III trial from agranulocytosis and associated severe adverse events possibly related to tozadenant.
Read the full text
VAP-1
Vascular Adhesion Protein-1 (VAP-1) monoclonal antibody - intended for treatment of inflammatory diseases, is currently in Phase I clinical trials with rheumatoid arthritis patients. According to the company, inhibiting VAP-1 reduces inflammation by regulating the migration of leukocytes, or white blood cells, to inflamed tissues. Pathological accumulation of white blood cells in tissue is a common feature in many autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, and psoriasis.
Nepicastat
SYN117 also called nepicastat is a treatment for cocaine dependency and post traumatic stress disorder (PTSD). It is orally administered, potent and selective inhibitor of the enzyme dopamine β-hydroxylase (DBH).
Ronomilast
Ronomilast is a PDE4 inhibitor for chronic inflammatory disorders. It is a small molecule phosphodiesterase-4 inhibitor (PDE4). The product is developed for the treatment of chronic obstructive pulmonary disease (COPD). Data from pre-clinical and early clinical trials indicates that the product has a good safety profile. Biotie is in the process of planning a Phase 2 trial in COPD patients and also seeking a partner for late-stage development of ronomilast.
From Wikipedia’s article on Biotie Therapies, shared under CC BY-SA 4.0.4
Subsidiaries and ownership
Subsidiaries
- Biotie Therapies (Switzerland)
From Wikidata.1
Timeline
- 1988Founded Founded1
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.biotie.com1
- WikipediaBiotie Therapies
- WikidataQ4915361
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataBiotie Therapies on Wikidata
- 2WikipediaBiotie Therapies on Wikipedia
- 3
- 4